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Marfan syndrome (MFS) is an autosomal 
dominant connective-tissue disorder asso-
ciated with abnormalities of the 
cardiovascular, ocular and musculoskel-
etal systems. Aortopathy, manifest as 
thoracic aortic aneurysm (TAA) and 
dissection, is the major cause of morbidity 
and mortality. Most individuals with MFS 
carry mutations in the gene FBN1. This 
gene encodes the extracellular matrix 
(ECM) protein fibrillin-1, which plays 
essential roles in the formation of microfi-
brils, organisation of ECM components 
and sequestration of growth factors such 
as transforming growth factor beta 
(TGFβ). Thus, mutations in FBN1 lead to 
deleterious biomechanical effects and 
aberrant signalling pathway activation 
within the aorta and other affected tissues.
Though autosomal dominant, MFS 
has wide phenotypic variability. For 
example, the age of onset, severity and 
rate of progression of TAA is currently 
unpredictable. These gaps in knowledge 
pose important limitations in clinical 
decision making with respect to timing 
of elective surgery, frequency of imaging 
follow-up, physical activity restriction and 
drug management. In their Heart paper, 
, Franken et al have undertaken the 
important task of investigating whether 
the specific subtype of FBN1 mutation 
could be used to predict the risk of TAA 
severity.1 The current study examined 
290 patients with MFS and known FBN1 
mutations followed at two specialist units, 
including Universitat Autonoma de Barce-
lona in Spain, and the Academic Medical 
Centre of Amsterdam, The Netherlands. 
The investigators tracked aortic diameter, 
aortic dilation rate and clinical endpoints 
of dissection and death from 2004 to 
2015.
The paThoGenesis of Mfs
Mutations in FBN1 can cause (1) reduction 
in the fibrillin produced in the cell, that is, 
quantitative defects, (2) change the struc-
ture or stability of the protein, and/or (3) 
alter the ability of fibrillin to be exported 
to the ECM (figure 1) . Mutations in 
FBN1 that result in haploinsufficiency 
(HI) lead to reduced amounts of fibrillin, 
fewer microfibrils and increased acti-
vated TGFβ levels due to decreased 
TGFβ sequestration. In contrast, domi-
nant negative (DN) mutations in FBN1 
result in qualitative defects of the protein 
that may affect function such as folding 
or protein–protein interactions leading 
to disorganisation of the ECM, altered 
ECM strength and increased TGFβ. The 
understanding of disease pathogenesis has 
been facilitated by mouse models of MFS 
that demonstrate the importance of HI.2 
Conceptually, DN mutations should result 
in more phenotypic variability because 
mutations at different region of the 
protein will have distinct effects, whereas 
HI mutations should have more consistent 
phenotypes. Only patients for whom a 
DN or HI mutation type could be assigned 
were studied by Franken et al. Along with 
software predictions, the authors also used 
existing literature to classify the functional 
effects of several specific variants in FBN1 
that were previously studied in detail 
in vitro. This interesting work presents 
evidence that patients with HI mutations 
have a greater aortic risk as compared 
with DN mutation carriers. Specifically, 
those patients with HI mutations had 
aortic surgery at a younger age (but similar 
overall rate of surgery), had a larger aortic 
root at the time of initial referral to their 
centres and showed more rapid dilation of 
the aortic root over the course of clinical 
follow-up.
GeneTics and MuTaTion Type in 
Mfs
Previous studies have also examined 
mutation type to determine whether 
genotype–phenotype correlations exist 
in MFS, dividing mutations into protein 
truncating or in-frame mutation types.3 4 
These studies fail to completely account 
for the effect of a mutation on the 
protein product. For example, a protein 
truncating mutation may result in HI or 
DN effects depending on the stability of 
the protein. Interestingly, there was no 
difference noted in aortic dilation when 
classifying mutations in this manner, but 
comparison within the in-frame group 
based on whether a cysteine residue was 
involved did show a significantly higher 
probability of aortic dilation and mitral 
valve prolapse.4 It would be of interest 
to determine whether the subset of DN 
mutations that alter cysteine residues 
show similar results in the current study. 
The current study’s approach to muta-
tion classification is more sophisticated 
and is supported by prior evidence that 
the software accurately predicts presence 
or absence of the mutated transcript.5 
Nevertheless, examples in the literature 
demonstrate that in order to assign HI 
versus DN effects with confidence, one 
must understand the mutation’s conse-
quences at the protein level.
A limitation for this retrospective study 
is that patients with the most severe 
disease who had aortic dissection or 
aortic replacement surgery (ARS) prior 
to referral to the centre were not eligible 
for longitudinal study. Mutations in exons 
24–32 are particularly associated with 
severe, early aortic disease. The majority 
of mutations in this region are missense 
or in-frame insertions/deletions, which 
manifest a more severe phenotype than 
the minority of truncating variants within 
this region,4 and a DN effect was observed 
in fibroblasts derived from patients with 
mutations in this region.6 The severe 
nature of these DN mutations seems to 
contradict the study’s major conclusion of 
HI mutations’ having more severe effects. 
One potential explanation would be that 
patients carrying in-frame variants in 
this region died at a young age or under-
went ARS and were thus ineligible for 
longitudinal study. Consistent with prior 
literature, patients with DN mutations in 
the study cohort were more likely to have 
ectopia lentis. This may have introduced 
an important ascertainment bias if ectopia 
lentis led to earlier diagnosis of MFS at 
referring centres and facilitated earlier 
initiation of medical therapies.
The wide phenotypic variability among 
patients with MFS includes variability 
even between relatives who carry the 
same mutation. Intrafamilial variability is 
a strong counterargument for classifying 
patients according to FBN1 genotype. 
Related individuals were included in this 
study for the majority of the analyses 
between HI and DN groups. There were 
169 probands among the 290 patients 
studied, with the remaining cohort 
comprised of relatives. It is interesting 
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figure 1 Genetics and pathogenesis in Marfan syndrome. A schematic overview of the effect of haploinsufficiency (HI) or dominant negative (DN) 
mutations is shown. The most common type of mutations that lead to HI or DN effect are listed. However, these classifications are not absolute, and 
the precise effect of a specific DNA mutation must be determined at the protein level. Mutations that cause HI result in less protein because only the 
normal, non-mutated FBN1 allele generates protein products. In contrast, a combination of normal protein products (fibrillin-1) generated by the non-
mutated FBN1 allele and stable abnormal protein products generated by the DN allele are seen with DN mutations. The green circle in the fibrillin-1 
protein represents the altered amino acid residue. Normal microfibrils are associated with latency associated peptides (LAP; red circles), which bind 
TGFβ in a biologically inactive complex in combination with latent TGFβ binding protein (LTBP1; blue oval). When microfibrils are reduced due to HI, 
interaction with matrix fibres is disrupted, and increases in activated TGFβ are seen due to a reduced number of microfibrils. DN mutations can have 
a range of effects depending on the specific mutation. Shown here, a DN mutation results in abnormalities in fibrillin-1 protein folding and increased 
activated TGFβ. TGFβ, transforming growth factor beta.
that when only one patient from each 
family was included, the SD of the rate of 
aortic root dilation decreased, in spite of 
an overall decrease in number tested. This 
indirectly suggests that including family 
members resulted in greater variability in 
aortic dilation. However, this could have 
been an artefact of how the patients were 
selected. Whether certain genotypes are 
more susceptible to specific genetic or 
environmental modifiers is an important 
question for future research.
cardiac phenoTypinG of paTienTs 
wiTh Mfs
In the longitudinal analyses of the current 
study, patients with HI mutations were 
found to have more rapid dilation than 
DN mutation carriers at the levels of the 
aortic root and the ascending aorta by 
approximately 0.3 mm/year. As the authors 
discuss, despite having a relatively large 
cohort, this study was still underpowered 
to conclusively evaluate differential risk of 
aortic dissection or need for ARS between 
HI and DN. Requirement for elective ARS 
is inherently vulnerable to variations in 
clinical practice, and institutional biases 
may have amplified the observations 
documented here. Given these limita-
tions, the authors used absolute aortic 
size as another marker of aortic disease 
severity. When using absolute aortic 
root size or dilation rate as an endpoint, 
it is important to appraise the specifics 
of centre practice variations, individual 
technical limitations, interval duration 
between measurements and, importantly, 
differences in overall body size. Though 
we would advocate adjusting aortic size 
relative to body surface area, we recognise 
important limitations to this approach. 
First, there are numerous published 
nomograms that substantially differ from 
one another due to inconsistent factors 
including different methods of diameter 
measurement (eg, in systole or diastole), 
distribution of ages, genders and race/
ethnicity within the reference population, 
formula for body surface area calculation 
and whether to include age and gender 
in Z-score calculations.7 8 Guidelines for 
timing of elective ARS are mostly based on 
absolute diameter, but the revised Ghent 
nosology uses a Z-score threshold as a 
criterion to diagnose MFS.9 10 This lack 
of a consensus approach for how to index 
aorta to body size hinders consistent clin-
ical care and creates research challenges. 
Given the important genotype–phenotype 
correlations identified in the current study, 
the design and interpretation of future 
validation studies will need to consider 
the method for determining aortic size. 
Based on the data provided for the current 
study, it appears that longitudinal analyses 
included children as young as age 5 years 
and included around 50 who were age 18 
or younger at the start of this study. This 
means that some of the observed growth 
in aortic size was physiological.11 Whether 
using Z-scores would alter the findings of 
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this study is undetermined, but at base-
line there were no differences between 
age, gender or body surface between 
mutation type groups. Finally, morpho-
logical and haemodynamic factors, such 
as bicuspid aortic valve and aortic regurgi-
tation, should be considered, if available, 
when assessing factors that control TAA 
progression.
precision diaGnosTics
Altogether, the current study makes an 
important stride towards improving 
cardiovascular risk classification of 
patients with MFS and supports the 
authors’ previous findings in the Dutch 
CONgenital CORvitia registry.12 The 
study detects an aortic phenotype 
difference based on FBN1 mutation clas-
sifications and stands as an example of the 
increasingly powerful capability to stratify 
patients based on individualised genetic 
testing results. Thus, the study shows the 
potential value of genotyping all patients 
with MFS and consideration of the role 
of allelic heterogeneity in management. In 
addition, the study highlights the value of 
large volume centres specialised in genetic 
and cardiac management of aortopathy to 
analyse robustly phenotyped cohorts and 
propel clinical practice forward. Whether 
and how the study’s main finding, that is, 
that HI mutations confer worse prognosis 
than DN mutations, should be incorpo-
rated into routine clinical management 
practices remains to be determined and 
will require follow-up in larger cohorts. 
There is prior evidence that mutation 
type may alter the patient’s response to 
losartan, providing promise for increas-
ingly tailored patient-specific therapy.5 
Additional mechanistic studies to deter-
mine how FBN1 mutation type alters 
aortic phenotype severity or response to 
medical therapies are warranted. Geno-
type–phenotype correlations promise to 
improve clinical management decisions to 
prevent adverse outcomes such as aortic 
dissection in higher risk patients and also 
to avoid unnecessary interventions in 
patients at lower risk.
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